Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer
- 9 September 2011
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 10 (2), 102-112
- https://doi.org/10.1111/j.1476-5829.2011.00280.x
Abstract
The purpose of this study was to assess the toxicoses and antitumor activity of metronomic chlorambucil at a dosage of 4 mg m−2 daily in dogs with naturally occurring cancer. Thirty‐six dogs were enrolled in the study. The protocol was well tolerated with no grade 3 or 4 toxicoses noted. Complete remission was achieved, and lasted over 35 weeks in three dogs (mast cell tumour, soft tissue sarcoma and thyroid carcinoma). Partial remission was noted in 1 dog with histiocytic sarcoma (39 weeks duration) for an overall remission rate of 11% (4 of 36). Stable disease was noted in 17 dogs (47%) with various other cancers. The median progression‐free interval was 61 days, and the median survival time was 153 days. Chlorambucil given in a metronomic protocol showed antitumor activity in dogs with a variety of naturally occurring cancers.Keywords
This publication has 46 references indexed in Scilit:
- Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor ActivityJournal of Biomedicine and Biotechnology, 2010
- Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary BladderMolecular Cancer Therapeutics, 2010
- The anticancer immune response: indispensable for therapeutic success?JCI Insight, 2008
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsBritish Journal of Cancer, 2008
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsNeuro-Oncology, 2007
- Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancerBMC Cancer, 2007
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals of Oncology, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000